Targeted RNA Sequencing Market Size, Share, Growth and Industry Analysis, By Types (Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing), By Applications (Research Institutes, Hospitals & Clinics), Regional Insights and Forecast to 2035

Targeted RNA Sequencing Market Size

The Global Targeted RNA Sequencing Market was valued at USD 3.36 Billion in 2025 and is projected to grow to USD 4.12 Billion in 2026, reaching USD 5.04 Billion in 2027. By 2035, the market is expected to expand significantly to USD 25.58 Billion, registering a robust CAGR of 22.5% from 2026 to 2035. This rapid growth is driven by rising adoption of precision medicine, advancements in genomics and transcriptomics technologies, and increasing demand for high-throughput, accurate RNA sequencing solutions in clinical research and drug development worldwide.

The U.S. targeted RNA sequencing market dominates North America, driven by advanced genomic research, increasing adoption of precision medicine, and strong government funding. In 2024, the U.S. accounted for approximately 65% of the regional market share.

The targeted RNA sequencing market is gaining significant traction due to its ability to provide high-resolution insights into gene expression and variation. This technique enables the identification of rare transcripts and mutations, offering more precise data than whole transcriptome sequencing. The global RNA sequencing market processed over 2.5 billion reads annually in 2023, reflecting the increasing adoption of this technology. The growing need for personalized medicine and advancements in sequencing technologies are fueling market growth. Increasing applications in oncology, genetic disorders, and infectious disease research are further driving demand. The rising integration of artificial intelligence (AI) and machine learning (ML) in data analysis is enhancing the accuracy and efficiency of targeted RNA sequencing, positioning it as a valuable tool in clinical and research settings.

Targeted RNA Sequencing Market Trends

The targeted RNA sequencing market is witnessing notable trends driven by technological advancements and increasing research activities. There is a growing shift toward single-cell RNA sequencing to enable more detailed gene expression profiling at the cellular level. For instance, single-cell RNA sequencing projects increased by over 30% in 2023, highlighting its growing importance in research. The development of next-generation sequencing (NGS) platforms with enhanced accuracy and reduced costs is encouraging more research institutions and pharmaceutical companies to adopt targeted RNA sequencing methods. The increasing focus on biomarker discovery and drug development is pushing the demand for targeted sequencing techniques to identify disease-specific RNA signatures.

Another key trend is the rise of automation and bioinformatics tools in RNA sequencing. Automation has improved sample processing efficiency by over 40% in the past five years, reducing human error and improving data quality. Bioinformatics platforms are enhancing data interpretation, making it easier for researchers to identify mutations and gene expression patterns. Additionally, there is an increasing number of partnerships between pharmaceutical companies and research organizations to leverage targeted RNA sequencing for precision medicine and targeted therapy development. The growing application of this technique in infectious disease research, particularly for COVID-19 variants and antimicrobial resistance, has led to the identification of over 1,500 RNA mutations linked to viral evolution.

Targeted RNA Sequencing Market Dynamics

The targeted RNA sequencing market is expanding rapidly due to its crucial role in understanding gene expression and mutations at a granular level. Unlike whole transcriptome sequencing, targeted RNA sequencing focuses on specific RNA regions, providing higher accuracy and reducing data complexity. In 2023, over 35% of RNA sequencing projects globally focused on targeted approaches due to their cost-effectiveness and enhanced data resolution. The growing demand for precision oncology and infectious disease research is driving market growth. Additionally, targeted RNA sequencing is proving instrumental in identifying fusion genes, with over 1,200 fusion events identified in cancer research over the last two years. This has accelerated the development of targeted therapies, positioning RNA sequencing as a critical tool in clinical and pharmaceutical research.

DRIVER FACTOR

"Rising demand for precision medicine"

The growing emphasis on personalized treatment approaches is significantly driving the targeted RNA sequencing market. Precision medicine relies heavily on detailed genetic information to tailor treatments, and targeted RNA sequencing provides valuable insights into gene expression variations. For example, targeted RNA sequencing has been instrumental in identifying novel biomarkers for cancer, leading to more effective targeted therapies. The increasing incidence of cancer, which accounted for approximately 19.3 million new cases worldwide in 2020, is boosting the adoption of targeted RNA sequencing in oncology research and treatment development. Furthermore, over 70% of precision oncology treatments currently under development are based on RNA sequencing data, underscoring its critical role in drug discovery and personalized medicine.

RESTRAINT

"High cost of sequencing technologies"

Despite technological advancements, the high cost associated with targeted RNA sequencing remains a major restraint. The cost of next-generation sequencing (NGS) platforms and related reagents can be prohibitive for small research institutions and developing markets. For instance, the cost of a single high-throughput sequencing run can range from $1,000 to $5,000, depending on the complexity and scale of the analysis. The need for specialized bioinformatics tools and skilled personnel further increases operational expenses, limiting market penetration in cost-sensitive regions. Additionally, the cost of sequencing reagents increased by 12% in 2023 due to supply chain disruptions, further adding to the financial burden.

OPPORTUNITY

"Increasing research in rare genetic disorders"

Growing research in rare and complex genetic disorders is creating new opportunities in the targeted RNA sequencing market. The ability to identify low-abundance transcripts and rare mutations is particularly valuable for understanding the genetic basis of rare diseases. For example, targeted RNA sequencing has been used to identify mutations linked to cystic fibrosis and Duchenne muscular dystrophy, leading to more targeted therapeutic strategies. The rise in funding for rare disease research, with over $1.5 billion allocated globally in 2023, is expected to fuel market growth. Moreover, over 7,000 rare diseases have been identified to date, and targeted RNA sequencing is being applied in over 1,000 active research projects focusing on rare genetic conditions.

CHALLENGE

"Data analysis complexity and interpretation"

The complexity of data analysis in targeted RNA sequencing presents a significant challenge for researchers and clinicians. The large volume of sequencing data requires advanced bioinformatics tools and expertise to extract meaningful insights. Variability in sample quality and sequencing depth can further complicate data interpretation. For instance, differences in library preparation methods can lead to inconsistent results, affecting the reliability of gene expression profiles. It is estimated that over 60% of sequencing errors stem from sample handling and preparation issues. The need for standardized protocols and more user-friendly bioinformatics solutions remains a key challenge in the market. Furthermore, the volume of data generated by a single RNA sequencing run can exceed 100 GB, creating storage and processing challenges for smaller laboratories.

Segmentation Analysis

The targeted RNA sequencing market is segmented by type and application, allowing for a detailed understanding of market dynamics and key growth areas. Segmentation by type includes exome sequencing, enrichment sequencing, and amplicon sequencing, each catering to different research and clinical needs. On the other hand, segmentation by application focuses on research institutes and hospitals & clinics, which are the primary drivers of demand. The growing need for precise genetic insights, advancements in sequencing technologies, and increased funding for genomics research are driving market expansion across all segments. Understanding these segments is crucial for identifying growth opportunities and strategic investments.

By Type

• Exome Sequencing: Exome sequencing holds a significant share of the targeted RNA sequencing market due to its ability to analyze protein-coding regions of the genome efficiently. This method provides insights into genetic variations linked to diseases, making it valuable for precision medicine and genetic research. According to market reports, exome sequencing accounted for approximately 30% of the total targeted RNA sequencing market in 2024. The growing adoption of exome sequencing in rare disease diagnosis and cancer research is expected to boost demand. Moreover, the decreasing cost of sequencing has made exome analysis more accessible to research institutions and healthcare providers.
• Enrichment Sequencing: Enrichment sequencing is gaining traction due to its high sensitivity and specificity in detecting low-frequency mutations. This method allows researchers to focus on specific genomic regions, improving data quality and reducing sequencing costs. In 2024, enrichment sequencing represented around 25% of the targeted RNA sequencing market. Its use in identifying gene fusions, transcript variations, and RNA editing events has increased in oncology and immunology research. The growing demand for personalized medicine and targeted therapies is expected to drive further adoption of enrichment sequencing in the coming years.
• Amplicon Sequencing: Amplicon sequencing is widely used for its cost-effectiveness and simplicity in analyzing genetic variations. It enables the detection of rare mutations and small genomic alterations with high accuracy. In 2024, amplicon sequencing accounted for approximately 20% of the total targeted RNA sequencing market. Its use in pathogen detection, microbial genomics, and infectious disease research has been a key growth driver. The increasing need for rapid and accurate diagnostic tools in clinical settings is expected to fuel market demand for amplicon sequencing.

By Application

• Research Institutes: Research institutes represent the largest application segment in the targeted RNA sequencing market, accounting for nearly 40% of the total market in 2024. The growing focus on genomics and transcriptomics research, along with increased funding from government and private organizations, has propelled demand. Targeted RNA sequencing is widely used in understanding gene expression patterns, identifying disease biomarkers, and developing new therapeutic strategies. The expansion of research facilities and collaborations with biotech firms are expected to further boost market growth in this segment.
• Hospitals & Clinics: Hospitals and clinics are rapidly adopting targeted RNA sequencing for diagnostic and therapeutic purposes. In 2024, this segment contributed to approximately 30% of the market. The ability of targeted RNA sequencing to provide precise genetic information has improved the diagnosis and treatment of cancer, neurological disorders, and infectious diseases. The growing focus on personalized medicine and the increasing availability of next-generation sequencing (NGS) platforms in clinical settings are driving market growth. The development of hospital-based genetic testing programs is expected to enhance the adoption of targeted RNA sequencing.

Targeted RNA Sequencing Market Regional Outlook

The targeted RNA sequencing market exhibits strong regional growth patterns, with North America, Europe, and Asia-Pacific emerging as key markets. The increasing prevalence of genetic disorders, advancements in sequencing technologies, and rising healthcare expenditures are driving regional market growth. Each region shows unique growth dynamics, influenced by government policies, healthcare infrastructure, and research capabilities.

North America

North America holds the largest share of the targeted RNA sequencing market, accounting for nearly 40% of the total market in 2024. The presence of leading biotechnology and pharmaceutical companies, along with strong government funding for genomics research, has driven market growth. The U.S. dominates the regional market due to the high adoption of next-generation sequencing (NGS) technologies and the presence of advanced research facilities. Additionally, initiatives such as the Precision Medicine Initiative and the Cancer Moonshot program have accelerated the use of targeted RNA sequencing in clinical and research settings.

Europe

Europe is a significant market for targeted RNA sequencing, contributing to approximately 30% of the global market in 2024. Countries such as Germany, the UK, and France are leading the adoption of RNA sequencing technologies. The growing focus on rare disease research and personalized medicine has increased demand for targeted RNA sequencing. The European Union’s funding for genomic research and the establishment of genomic data-sharing platforms have supported market growth. Additionally, partnerships between academic institutions and biotech companies are expected to further strengthen the regional market.

Asia-Pacific

The Asia-Pacific region is witnessing the fastest growth in the targeted RNA sequencing market, representing about 20% of the total market in 2024. The rapid expansion of healthcare infrastructure, increasing investments in biotechnology, and rising awareness of precision medicine are driving market growth. China, Japan, and India are leading the adoption of targeted RNA sequencing technologies. Government initiatives to promote genomics research and the establishment of national genomic databases are expected to boost market demand. The increasing presence of global sequencing companies in the region is also contributing to market expansion.

Middle East & Africa

The Middle East & Africa (MEA) region is experiencing steady growth in the targeted RNA sequencing market, driven by increasing investments in healthcare infrastructure and rising demand for personalized medicine. Countries such as the United Arab Emirates (UAE), Saudi Arabia, and South Africa are key contributors to market expansion. The UAE and Saudi Arabia are focusing on genomic research and precision medicine initiatives, contributing to the demand for targeted RNA sequencing solutions. In 2024, South Africa accounted for approximately 35% of the MEA market share, driven by increased research funding and government initiatives to enhance healthcare capabilities. Furthermore, partnerships between local research institutions and global biotechnology firms are expanding the availability of advanced RNA sequencing technologies. The demand for RNA-based diagnostics and biomarker identification for diseases such as cancer and infectious diseases is also rising, with government-backed initiatives in Saudi Arabia and the UAE investing over $200 million in genomic research and biotechnology.

LIST OF KEY Targeted RNA Sequencing Market COMPANIES PROFILED

• Thermo Fisher
• Illumina
• Roche Holdings
• BGI
• Eurofins
• LabCorp
• Berry Genomics
• Macrogen
• GENEWIZ

Top Two Companies with Highest Market Share:

• Illumina – Approximately 35% market share
• Thermo Fisher – Approximately 28% market share

Investment Analysis and Opportunities

Investment in the targeted RNA sequencing market is increasing, driven by advancements in genomics and the rising demand for precision medicine. In 2023, over $2.5 billion was invested globally in RNA sequencing technologies, with North America accounting for nearly 45% of the total investment. Government funding and private investments are fueling research and development, particularly in cancer diagnostics and infectious disease management. In Europe, the Horizon Europe program allocated over €300 million toward genomic research in 2023, boosting the development of targeted RNA sequencing platforms. Asia-Pacific is also witnessing significant investment growth, with China contributing over $500 million to genomic research in 2024, supported by the government's "Healthy China 2030" initiative. Investment in infrastructure and technology, including next-generation sequencing (NGS) platforms and bioinformatics solutions, is expanding the market’s capacity and improving sequencing accuracy. Strategic collaborations between pharmaceutical companies and sequencing technology providers are creating new opportunities for targeted RNA sequencing applications in drug discovery, disease monitoring, and personalized therapies. Moreover, increased funding for rare disease research and oncology biomarkers is driving innovation and expanding the market's potential.

NEW PRODUCTS Development

New product development in the targeted RNA sequencing market is accelerating as companies seek to enhance sequencing accuracy and reduce turnaround times. In 2023, Illumina launched the NovaSeq X Series, which increased sequencing speed by 50% while reducing costs by 20% per sample. Thermo Fisher introduced the Ion Torrent Genexus System, an automated platform that enables results within 24 hours from sample to report, streamlining the workflow for clinical and research applications. In 2024, BGI released the DNBSEQ-G99, which features an ultra-high throughput capacity and enhanced accuracy for single-cell RNA sequencing. Eurofins also launched an advanced bioinformatics platform that allows for real-time data analysis and reporting, reducing data processing time by 30%. Roche introduced a next-generation targeted RNA panel that enhances the detection of fusion transcripts and rare variants, improving diagnostic sensitivity by over 25%. These new products reflect the growing demand for more accurate, faster, and cost-effective targeted RNA sequencing solutions, driving increased adoption in both clinical and research settings.

Five Recent Developments by Manufacturers

• Illumina (2023) – Launched the NovaSeq X Series, offering a 50% increase in sequencing speed and a 20% reduction in cost per sample.
• Thermo Fisher (2023) – Released the Ion Torrent Genexus System, enabling same-day results with a 24-hour turnaround time.
• BGI (2024) – Unveiled the DNBSEQ-G99, featuring enhanced throughput and improved single-cell RNA sequencing capabilities.
• Roche (2024) – Introduced an upgraded RNA fusion detection panel with a 25% increase in sensitivity for rare variants.
• Eurofins (2023) – Launched a bioinformatics platform that reduces data processing time by 30% and supports real-time analysis.

REPORT COVERAGE of Targeted RNA Sequencing Market

The report on the targeted RNA sequencing market provides comprehensive coverage of key market dynamics, including trends, drivers, restraints, opportunities, and challenges. It examines market segmentation by technology, application, and end-user, with detailed regional analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The report offers in-depth profiling of major market players such as Illumina, Thermo Fisher, Roche, BGI, and Eurofins, analyzing their market share, product offerings, and strategic initiatives. It includes a detailed analysis of new product launches, technological advancements, and investment trends. Market drivers such as the rising demand for precision medicine, advancements in next-generation sequencing (NGS) technology, and increased funding for genomic research are explored. Restraints, including high sequencing costs and data analysis complexity, are also discussed. The report covers emerging opportunities in personalized oncology, infectious disease diagnostics, and drug discovery, supported by government funding and strategic partnerships. Additionally, it provides a five-year forecast, competitive landscape analysis, and insights into market entry barriers, regulatory frameworks, and evolving customer needs.